Customer reviews tell pharma brands very little about AI visibility services today. The falsifiable position is simple: reviews are not yet a reliable primary signal because the category is new, review volume is thin, and existing reviews come from unrelated verticals. No pharma-specific review corpus exists at usable volume on major review platforms, so buyers need a different evaluation method.

Disclosure: the author founded AEO Dose, which provides AI visibility and AEO readiness audits for pharma businesses. The service design referenced here comes from that work. The ownership relationship is real and worth naming so readers can weigh the evaluation framework with that context.

Why the AI visibility service category is too new for review aggregators

The AI visibility service category is too new for review aggregators because buyer behavior shifted faster than review taxonomies did. As of this quarter, a pharma marketing lead can find mature review categories for SEO, paid media, analytics, and marketing agencies. That does not mean the same platforms contain a usable pharma-specific corpus for AEO services, GEO services, or AI visibility audits.

That gap matters because this is not a generic software purchase. A CDMO, API manufacturer, excipient supplier, nutraceutical brand, or oral care product manufacturer needs to know whether an AI visibility vendor understands regulated product language, buyer qualification, technical capability pages, and supplier shortlisting behavior. A five-star review from an unrelated B2B category does not answer that.

There is also a timing problem. Buyers have only recently started asking ChatGPT, Gemini, Perplexity, Claude, and Grok to compare suppliers, explain capabilities, or shortlist vendors. Review aggregators were built around older decision signals: software usability, service satisfaction, account support, and project delivery. Those signals still have value, but they do not measure whether a vendor can test how AI assistants retrieve, summarize, and cite a pharma business.

This is where the industry habit of asking "who has the best reviews" becomes misallocated effort. That question assumes a mature category with enough comparable reviews to support judgment. Pharma AEO does not have that yet. The better question is: what does the vendor test, how do they test it, and can they show the evaluation logic before you sign?

What review signals exist today and what they miss for pharma buyers

The review signals that exist today are adjacent signals, not pharma-specific proof of AI visibility competence. Buyers may find general agency reviews, SEO service ratings, testimonials, case-study language, LinkedIn comments, webinar feedback, or informal referrals. Each can provide context, but none should be treated as direct evidence that an AEO service can evaluate pharma visibility inside AI assistants. Platforms such as G2 category pages for SEO and marketing services list AEO-adjacent services under broad marketing headings rather than a dedicated AI visibility category for pharma.

The limitation is not that reviews are useless. A poor pattern of responsiveness, vague communication, or unsupported claims is still worth noticing. The limitation is category fit. A review about a website redesign does not tell you whether the vendor can build buyer-journey prompts for an API manufacturer. A testimonial about content output does not tell you whether the vendor checks how Perplexity cites third-party sources. A positive agency review does not disclose whether ChatGPT, Gemini, Claude, Grok, and Perplexity were all tested separately.

For pharma buyers, the missing layer is operational detail. Reviews do not show the question set used in the audit. They do not show whether the vendor separates discovery questions from evaluation, product or capability, commercial, and support questions. They do not show whether regulated terminology was checked with care. They do not show whether the reporting format separates visibility gaps from content gaps, technical entity gaps, and authority gaps.

So treat reviews as background context, not a selection method. If review data exists, read it for service hygiene: clarity, responsiveness, follow-through. Then move to evidence that is specific to AI visibility and pharma buying behavior.

The evaluation criteria reviews cannot surface: platform coverage, question quality, methodology

Reviews cannot surface the evaluation criteria that matter for AEO because those criteria sit inside the audit design. Three areas deserve direct inspection: platform coverage, buyer-journey question quality, and methodology disclosure. These are members of an evaluation set; none ranks above the others, and each answers a different question.

Platform coverage means naming the AI systems tested, not saying "AI search" as a blanket phrase. In AEO Dose's service design, the Free AI Visibility Check covers 2 platforms and 10 buyer questions, while the Full Audit covers ChatGPT, Gemini, Perplexity, Claude, and Grok. That is not presented here as a universal standard. It is a concrete example of what we check so a buyer can compare whether another vendor is equally specific. In the absence of platform coverage detail, you are buying a claim rather than a measurement.

Buyer-journey question quality means the audit should reflect how pharma buyers ask, not just how marketers describe the brand. A credible question set separates at least these themes: discovery, evaluation, product or capability, commercial, and support. For example, "Who supplies pharmaceutical excipients for oral solid dosage?" is a different test from "Compare CDMOs with sterile fill-finish capability for a clinical-stage sponsor." The second question carries buyer context, qualification, and comparison intent.

Methodology disclosure means the vendor can explain how prompts are selected, how platforms are run, how outputs are recorded, and how findings are categorized. It should also cover what the vendor inspects on the company site: entity clarity, service pages, author and organization signals, article structure, source consistency, and freshness. If structured markup is part of the review, the vendor should say what they check rather than using schema as a vague credibility word. The Schema.org Article vocabulary is one public example of the structured data AI systems can parse; a vendor who checks it should be able to name the properties they look for.

Pharma-specific domain experience also belongs in evaluation. My background is B.Pharma, with 12+ years across Pharma ERP implementation and Computer System Validation. That experience does not make a framework correct by itself, but it explains why I separate technical visibility claims from regulated-market execution details.

What to ask an AI visibility vendor during evaluation

A pharma buyer should ask questions that force the vendor to reveal the test design, not just the sales narrative. Start with platform coverage: "Which AI assistants will you test, and will you report results separately for each one?" If the response collapses all platforms into one generic score, ask how that score is produced.

Then move to question design: "How will you build buyer questions for our category?" A CDMO, API manufacturer, excipient supplier, nutraceutical brand, and oral care product manufacturer do not share the same buying path. If the vendor cannot explain discovery, evaluation, product or capability, commercial, and support themes, the audit may become a keyword report with AI language attached.

Ask how the vendor handles repeatability: "Will you preserve the prompts, dates, platform names, and outputs used in the audit?" AI responses can shift. A credible report should make the test conditions visible enough that a buyer can interpret the finding without treating it as magic.

Ask about reporting format: "Will recommendations be separated by content, technical site structure, entity consistency, third-party evidence, and measurement?" That separation prevents wasted budget. If every answer is "write more content," the service is not diagnosing the system around visibility.

Finally, ask about process cycle. A practical AEO program should describe a cycle such as Audit, Optimize, Build Authority, Measure, Repeat. The words are less important than the discipline: diagnose first, change specific assets, reinforce evidence, measure again, and avoid claiming certainty where AI systems remain variable. For companion material on evidence requests and pitch red flags, see the Checking Reviews for AI Services resource hub.

What evidence to request before signing

Before signing, request evidence that shows how the vendor thinks, not just what the vendor promises. The buyer should ask for a sample report outline, a sample prompt set, and a clear explanation of how findings are classified. The vendor does not need to disclose another client's confidential data, but they should be able to show report structure and evaluation logic.

Request platform-level reporting. A useful audit does not hide platform variation behind a single blended conclusion. ChatGPT, Gemini, Perplexity, Claude, and Grok can produce different supplier mentions, different source patterns, and different summaries. A buyer needs to see which platform was tested and what happened in that environment.

Request question-level evidence. If the vendor says your brand is invisible for evaluation queries, ask to see the exact question family behind that conclusion. If the vendor says your service page lacks entity clarity, ask which page, which term, and which AI response pattern exposed the weakness.

Request methodology boundaries. A vendor should be able to say what the audit does not measure. It may not measure final purchasing behavior. It may not guarantee mention improvement. It may not prove that one content change caused one AI answer to change. Those boundaries are not weakness. They are evidence of restraint.

Request a response-time and process-cycle explanation. A credible process should tell you when the initial check happens, when findings are delivered, what optimization work follows, and when re-measurement occurs. Without that cycle, the buyer is purchasing a snapshot with no practical path to action.

A short checklist pharma buyers can use this week

A pharma buyer can use this checklist in the next vendor call to replace review-chasing with evidence-based evaluation. Keep it short, direct, and tied to the work you need the vendor to perform.

Ask these questions:

  1. Which AI platforms will you test, and will the results be reported separately?
  2. How many buyer questions will you test, and how are they built for our category?
  3. Do the questions cover discovery, evaluation, product or capability, commercial, and support intent?
  4. Will we see the prompts, dates, platform names, and output examples behind the findings?
  5. How do you separate content gaps, entity gaps, technical site gaps, and authority gaps?
  6. What parts of our site structure and markup will you inspect?
  7. What will your report tell us to change first without claiming guaranteed visibility?
  8. When do you measure again after optimization work is completed?

If a vendor can answer those questions clearly, reviews become less central. If they cannot, positive review language will not repair the methodological gap.

Get Your Free AI Visibility Check

Start Your Free Check

Frequently asked questions

Can customer reviews help pharma brands choose an AI visibility service?
Customer reviews can help with basic service hygiene, such as communication style, responsiveness, and follow-through. They should not be treated as direct evidence of AEO capability in pharma. The category is new enough that review platforms do not yet provide a usable pharma-specific review corpus. Pharma buyers should use reviews as background context, then request platform coverage, question design, methodology disclosure, and sample reporting before making a decision.
Why are general SEO or agency reviews not enough for AEO evaluation?
General SEO or agency reviews usually describe satisfaction with broader marketing work, not whether a vendor can test AI assistant answers for pharma buyer questions. AEO evaluation requires platform-specific testing, prompt documentation, source analysis, and category-aware interpretation. A review about website traffic or content delivery does not prove the vendor can evaluate how ChatGPT, Gemini, Perplexity, Claude, or Grok mention a CDMO, API manufacturer, excipient supplier, or related pharma business.
What should pharma buyers ask an AI visibility vendor before signing?
Ask which AI platforms will be tested, how buyer questions are selected, whether results are reported by platform, and whether the vendor preserves prompts, dates, outputs, and source patterns. Also ask how the report separates content gaps from technical site issues, entity consistency gaps, and authority gaps. These questions reveal whether the service has an audit method or is repackaging generic SEO advice with AI terminology.
What evidence should a pharma buyer request from an AEO service?
Request a sample report outline, an anonymized prompt set, a description of the methodology, and an explanation of the process cycle after the audit. The vendor should be able to show how findings are classified without disclosing confidential client data. Ask for platform-level reporting and question-level evidence so you can see the logic behind conclusions rather than relying on broad claims about AI visibility.
How does buyer-journey question quality separate serious AEO services from generic ones?
Buyer-journey question quality matters because pharma buyers do not ask only brand-name or keyword-style questions. They ask discovery, evaluation, capability, commercial, and support questions. A generic prompt set can miss the way a sponsor compares CDMOs, how a manufacturer evaluates excipient suppliers, or how a commercial team searches for category-specific partners. Question quality shows whether the vendor understands the buying path being tested.